We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




C-Reactive Protein Predicts Neurological Outcomes of Subarachnoid Hemorrhage Patients

By LabMedica International staff writers
Posted on 07 Apr 2020
Subarachnoid hemorrhage (SAH) is a disease associated with high mortality. More...
Survivors of SAH may manifest severe neurological deficits. In patients with SAH, early brain injury or delayed cerebral ischemia (DCI) is associated with poor outcomes.

C-reactive protein (CRP) is a useful marker of non-specific inflammation. Elevated CRP levels might be associated with the progression of vascular disease. Elevated levels of CRP are significantly associated with unfavorable long-term functional outcome in patients with ischemic stroke. The measurement of CRP significantly increases the ability to make accurate predictions and prevent or manage coronary thrombotic events appropriately.

Neurologists at the Samsung Medical Center (Seoul, Republic of Korea) carried out a retrospective, single-center, observational study of adult patients with SAH who were admitted to the neurosurgical intensive care unit (ICU) from January 2012 through June 2017. A total of 156 patients diagnosed with SAH were analyzed in the study. Initial brain CT and CT angiography were performed within 12 hours from the onset of SAH.

Initial CRP levels were measured within 12 hours after admission. The day of admission was defined as day 1. CRP data on days 1 to 7 were collected. Serum CRP levels were measured using the CRPL3 immunoturbidimetric assays (Roche Diagnostics, Indianapolis, IN, USA) with a lower reference limit of 0.3 mg/dL. The maximal level of CRP (CRPMax) was defined as the peak level from days 1 through 4. Subsequent CRP (CRPmin) level was determined as the minimal level from days 5 to 7.

The scientists reported that among 156 patients with SAH, 145 (92.9%) survived until discharge. Of these survivors, 109 (69.9%) manifested favorable neurological outcomes. Initial CRP levels on admission and maximal CRP levels within four days were significantly higher in the group with poor neurological outcome compared with those manifesting favorable neurological outcomes. Prediction of poor neurological outcome showed that the performance of the maximal CRP was significantly better compared with the initial CRP or the clearance of CRP. The maximal CRP levels within four days facilitate the prediction of neurological outcomes of SAH patients without surgical clipping.

The authors concluded that early serial measurements of CRP may be used to predict neurological outcomes of SAH patients. Furthermore, maximal CRP levels within four days post-SAH are significantly correlated with poor neurological outcomes. The study was published on march 27, 2020 in the journal BMC Neurology.

Related Links:
Samsung Medical Center
Roche Diagnostics



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.